Differences

Last edited on October 12, 2023

This shows you the differences between two versions of the page.

--- geri:dementia:vascular [on February 9, 2022]
psychdb
+++ geri:dementia:vascular [on October 12, 2023]
psychdb
@@ Line 5: / Line 5: @@
 == Epidemiology ==
+  * The prevalence is higher in males than in females.
   * The prevalence for vascular dementia ranges from 0.2% in the 65-70 years age group to 16% in 80 years and older.
   * Within 3 months post-stroke, 20%-30% of individuals are diagnosed with dementia.
-  * The prevalence is higher in males than in females.
+  * It is suggested that the vascular dementia is overdiagnosed, as non-significant cerebrovascular lesions may be overcalled as the main etiology for the presenting dementia.[([[https://pubmed.ncbi.nlm.nih.gov/25633672/|Niemantsverdriet, E., Feyen, B. F., Le Bastard, N., Martin, J. J., Goeman, J., De Deyn, P. P., & Engelborghs, S. (2015). Overdiagnosing vascular dementia using structural brain imaging for dementia work-up. Journal of Alzheimer's Disease, 45(4), 1039-1043.]])][([[https://pubmed.ncbi.nlm.nih.gov/3291834/|Brust, J. C. (1988). Vascular dementia is overdiagnosed. Archives of Neurology, 45(7), 799-801.]])]
 == Prognosis ==
@@ Line 227: / Line 229: @@
 ==== Pharmacotherapy ====
-Acetylcholinesterase inhibitors ([[meds:dementia:donepezil|donepezil]], [[meds:dementia:rivastigmine|rivastigmine]], and [[meds:dementia:galantamine|galantamine]]) as a class are modestly efficacious for patients with mixed AD and vascular dementia pathology, and a trial of these medications is recommended for most patients diagnosed with AD.[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980908/|Herrmann, N., Lanctôt, K. L., & Hogan, D. B. (2013). Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimer's research & therapy, 5(1), S5.]])] However, in //isolated// vascular dementia, there is insufficient and inconsistent evidence support on whether acetylcholinesterase inhibitors are effective.[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980908/|Herrmann, N., Lanctôt, K. L., & Hogan, D. B. (2013). Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimer's research & therapy, 5(1), S5.]])]
+  * Acetylcholinesterase inhibitors ([[meds:dementia:donepezil|donepezil]], [[meds:dementia:rivastigmine|rivastigmine]], and [[meds:dementia:galantamine|galantamine]]) as a class are modestly efficacious for patients with mixed AD and vascular dementia pathology, and a trial of these medications is recommended for most patients diagnosed with AD.[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980908/|Herrmann, N., Lanctôt, K. L., & Hogan, D. B. (2013). Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimer's research & therapy, 5(1), S5.]])]
+  * However, in //isolated// vascular dementia, there is insufficient and inconsistent evidence support on whether acetylcholinesterase inhibitors are effective.[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980908/|Herrmann, N., Lanctôt, K. L., & Hogan, D. B. (2013). Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimer's research & therapy, 5(1), S5.]])]
 <panel type="info" title="Pharmacotherapy for Vascular Dementia" subtitle="Ritter, A., and Pillai, J. A. (2015). Treatment of vascular cognitive impairment. Current treatment options in neurology, 17(8), 35." no-body="true" footer="">